Efficacy of Octreotide-LAR in Dieting Women with Abdominal Obesity and Polycystic Ovary Syndrome
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Context: Somatostatin reduces LH, GH, and insulin, and somatostatin receptors are present at the ovarian level; somatostatin analogs are thus potential candidates for treatment of the polycystic ovary syndrome (PCOS). Objective: The purpose of this study was to evaluate the effect of octreotide-LAR, a long-acting somatostatin analog, in anovulatory abdominal obese women with PCOS. Design: A single-blind, placebo-controlled study was performed, lasting for 7 months. Setting: The patients were ambulatory throughout the study. Patients: Twenty PCOS subjects were enrolled. Eighteen completed the study. Interventions: A low-calorie diet was given during the first month, a low-calorie diet plus octreotide-LAR (10 mg; n = 10 subjects) or placebo (n = 10 subjects) was then given, with one im injection every 28 d (for 6 months). Main Outcome Measures: The main outcome measures were clinical features, computerized tomography measurement of fat distribution, androgens, GH, IGF-I, IGF-binding proteins (IGFBPs), fasting and glucose-stimulated insulin, and ovulation. Results: Octreotide had no additional effect in reducing body fat or improving fat distribution than placebo. Conversely, octreotide produced an additional decrease in fasting (P = 0.018) and glucose-stimulated (P = 0.038) insulin levels, an increase in IGFBP-2 (P = 0.042) and IGFBP-3 (P = 0.047), and an improvement in hirsutism (P = 0.004). Moreover, a trend toward greater reductions in testosterone (P = 0.061) and androstenedione (P = 0.069) was observed in women treated with octreotide-LAR compared with those given placebo. All women treated with octreotide ovulated at the end of the study compared with only one of those receiving placebo (P < 0.001). Conclusions: Octreotide-LAR may be usefully applied to hypocalorically dieting, abdominal obese PCOS women to improve hyperandrogenism and the insulin-IGF-I system. Restoration of ovulatory menstrual cycles appears to be another advantage of this treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635
Self-citationMather, K. J., Hunt, A. E., Steinberg, H. O., Paradisi, G., Hook, G., Katz, A., Quon, M. J., & Baron, A. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.7880 · Cited by 363
Gambineri, A., Pelusi, C., Genghini, S., Morselli‐Labate, A. M., Cacciari, M., Pagotto, U., & Pasquali, R. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01973.x · Cited by 216 · cited 3×
“A computerized tomography (CT) scan measurement of body fat distribution was also performed at the level of L4–L5 to estimate total (TAT), visceral (VAT), and sc (SAT) adipose tissue areas (25).”
MethodResultSelf-citationFulghesu, A. M., Villa, P., Pavone, V., Guido, M., Apa, R., Caruso, A., Lanzone, A., Rossodivita, A., & Mancuso, S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3727 · Cited by 128
Research works printed but not linked: 31
- 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome., Hum Reprod, 19, 41, 10.1093/humrep/deh098 · DOI · Paper page
- Gambineri, 2002, Obesity and the polycystic ovary syndrome., Int J Obes Rel Metab Disord, 26, 883, 10.1038/sj.ijo.0801994 · DOI · Paper page
- Franks, 2003, Assessment and management of anovulatory infertility in polycystic ovary syndrome., Endocrinol Metab Clin North Am, 32, 639, 10.1016/S0889-8529(03)00044-6 · DOI
- Poretsky, 1999, The insulin-related ovarian regulatory system in health and disease., Endocr Rev, 20, 535, 10.1210/edrv.20.4.0374 · DOI · Paper page
- Morales, 1996, Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distintict features., J Clin Endocrinol Metab, 81, 2854
- Chiodera, 1986, Inhibition by somatostatin of LHRH-induced LH release in normal mestruating women., Gynecol Obstet Invest, 22, 17, 10.1159/000298884 · doi:10.1159/000298884
- Brazaan, 1973, Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone., Science, 179, 77, 10.1126/science.179.4068.77 · DOI · Paper page
- Hsu, 1991, Somatostatin inhibits insulin secretion by a G-protein-mediated decrease in Ca2+ entry through voltage-dependent Ca2+ channels in the β-cell., J Biol Chem, 266, 837, 10.1016/S0021-9258(17)35249-3 · DOI · Paper page
- Patel, 1990, Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor protein., Metabolism, 39, 63, 10.1016/0026-0495(90)90214-W · doi:10.1016/0026-0495(90)90214-w
- Prevelic, 1990, Inhibitory effect of sandostatin on secretion of luteinizing hormone and ovarian steroids in polycystic ovary syndrome., Lancet, 336, 900, 10.1016/0140-6736(90)92270-R · DOI
- Prevelic, 1992, Effects of the somatostatin analogue, octreotide, in polycystic ovary syndrome., Metabolism, 41, 76, 10.1016/0026-0495(92)90036-A · DOI
- Prevelic, 1995, The effects of the somatostatin analogue octreotide on ovulatory performance in women with polycystic ovaries., Hum Reprod, 10, 28, 10.1093/humrep/10.1.28 · doi:10.1093/humrep/10.1.28
- Morris, 1995, Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ovary syndrome., Fertil Steril, 63, 742, 10.1016/S0015-0282(16)57475-5 · DOI
- Fulghesu, 1995, Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease., Fertil Steril, 64, 703, 10.1016/S0015-0282(16)57842-X · DOI
- Morris, 1999, Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome., Fertil Steril, 71, 452, 10.1016/S0015-0282(98)00475-0 · DOI
- Lidor, 1998, Combined somatostatin analog and follicle-stimulating hormone for women with polycystic ovary syndrome resistant to conventional treatment., Gynecol Endocrinol, 12, 97, 10.3109/09513599809024957 · DOI
- Ciotta, 1999, Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinemia or normoinsulinemia., Hum Reprod, 14, 2951, 10.1093/humrep/14.12.2951 · DOI
- Wenzl, 1996, Successful ovulation induction by sandostatin-therapy of polycystic ovarian disease., Acta Obstet Gynecol Scand, 75, 298, 10.3109/00016349609047106 · doi:10.3109/00016349609047106
- Gillis, 1997, Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly., Drugs, 53, 681, 10.2165/00003495-199753040-00009 · DOI
- Nestler, 1998, Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome., N Engl J Med, 338, 1876, 10.1056/NEJM199806253382603 · DOI · Paper page
- Ferriman, 1961, Clinical assessment of body hair growth in women., J Clin Endocrinol Metab, 21, 1440, 10.1210/jcem-21-11-1440 · DOI · Paper page
- Hud, 1992, Prevalence and significance of acanthosis nigricans in an adult obese population., Arch Dermatol, 128, 941, 10.1001/archderm.1992.01680170073009 · doi:10.1001/archderm.1992.01680170073009 · Paper page
- Baecke, 1982, A short questionnaire for the measurement of habitual physical activity in epidemiological studies., Am J Clin Nutr, 36, 939, 10.1093/ajcn/36.5.936 · DOI · Paper page
- Pasquali, 1999, The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment., Clin Endocrinol (Oxf), 50, 517, 10.1046/j.1365-2265.1999.00701.x · DOI · Paper page
- Garrone, 2002, Increased insulin-like growth factor (IGF)-II and IGF/IGF-binding protein ratio in prepubertal constitutionally tall children., J Clin Endocrinol Metab, 87, 5455, 10.1210/jc.2002-020614 · DOI
- Pagotto, 2002, Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels., J Clin Endocrinol Metab, 87, 5625, 10.1210/jc.2002-020776 · DOI · Paper page
- Vermeulen, 1999, A critical evaluation of simple methods for the estimation of free testosterone in serum., J Clin Endocrinol Metab, 84, 3666, 10.1210/jcem.84.10.6079 · DOI · Paper page
- Matsuda, 1999, Insulin sensitivity indices obtained from oral glucose tolerance testing., Diabetes Care, 22, 1462, 10.2337/diacare.22.9.1462 · DOI · Paper page
- Bertoli, 1996, Dose-dependent effect of octreotide on insulin secretion after OGTT in obesity., Horm Res, 49, 17
- Barkan, 2003, Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels., J Clin Endocrinol Metab, 88, 2180, 10.1210/jc.2002-021169 · DOI · Paper page
- Pawelezyk, 1993, Sandostatin has no direct effect on ovarian steroidogenesis in vitro., Hum Reprod, 8, 346
Cited by
Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2573 · Cited by 1,282
Gambineri, A., Patton, L., Vaccina, A., Cacciari, M., Morselli-Labate, A. M., Cavazza, C., Pagotto, U., & Pasquali, R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2250 · Cited by 221
Self-citationThe management of patients with polycystic ovary syndrome
Jayasena, C. N., & Franks, S. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.102 · Cited by 196
Hyperandrogenism and Polycystic Ovary Syndrome in Women with Type 1 Diabetes Mellitus
Codner, E., & Escobar-Morreale, H. F. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2641 · Cited by 112
Interventions for hirsutism (excluding laser and photoepilation therapy alone)
van Zuuren, E. J., Fedorowicz, Z., Carter, B., & Pandis, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010334.pub2 · Cited by 65
Pandurevic, S., Mancini, I., Mitselman, D., Magagnoli, M., Teglia, R., Fazzeri, R., Dionese, P., Cecchetti, C., Caprio, M., Moretti, C., et al. (2023) · Endocrine Connections · doi:10.1530/ec-22-0536 · Cited by 36
Self-citationZuuren, E. J., & Fedorowicz, Z. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14486 · Cited by 35
Suppression of insulin secretion in the treatment of obesity: a systematic review and meta-analysis
Huang, Z., Wang, W., Huang, L., Guo, L., & Chen, C. (2020) · Obesity · doi:10.1002/oby.22955 · Cited by 13
“Gambineri’s study (30) had high performance and detection bias because of a single-blind intervention.”
BackgroundResult
Metadata
- Authors
- Gambineri, A., Patton, L., De Iasio, R., Cantelli, B., Cognini, G. E., Filicori, M., Barreca, A., Diamanti-Kandarakis, E., Pagotto, U., & Pasquali, R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-07-01
- Volume
- 90
- Issue
- 7
- Pages
- 3854-3862
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2006659599
- Cited by
- 47
- References
- 6
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.